Mounjaro Eligible Patients BMI UK Criteria - From £124.99

Clinically Proven UK Registered Pharmacy

Cheapest Mounjaro UK - Eligible Patients BMI Criteria £124.99

Get Mounjaro at the cheapest UK price from £124.99 with £20 off using code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Understanding Mounjaro Eligible Patients BMI UK Criteria for Weight Loss Treatment

Published: 27 August 2026

The mounjaro eligible patients bmi uk criteria determine who can access this licensed tirzepatide treatment through UK prescribers. As a GPhC-registered pharmacy with superintendent pharmacist Tarun Kumar overseeing clinical protocols, we ensure every patient meets the MHRA-approved eligibility thresholds before prescribing. Mounjaro is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities, subject to clinical assessment by our UK-registered prescribers.

Core Mounjaro Eligible Patients BMI UK Criteria Explained

The mounjaro eligible patients bmi uk criteria follow MHRA licensing standards established for tirzepatide in weight management. Adults must have a body mass index of at least 30 kg/m², classified as obese, or a BMI of 27 kg/m² alongside at least one weight-related health condition such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea [1]. These thresholds align with clinical trial inclusion criteria from the SURMOUNT studies, which demonstrated significant weight reduction in participants meeting these parameters.

Beyond BMI measurements, mounjaro eligible patients bmi uk criteria require assessment of contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease [2]. Our UK prescribers evaluate each patient's medical history during the online consultation, which takes under three minutes to complete. Patients with a history of pancreatitis, severe renal impairment, or diabetic retinopathy require careful evaluation before approval, as tirzepatide may not be suitable in these circumstances.

How BMI Thresholds Define Mounjaro Eligible Patients BMI UK Criteria

Body mass index serves as the primary metric in mounjaro eligible patients bmi uk criteria because it provides a standardised measure of weight relative to height. A BMI of 30 kg/m² represents the clinical threshold for obesity in UK practice, whilst 27 kg/m² with comorbidities captures patients at elevated metabolic risk who may benefit from pharmaceutical intervention [3]. The SURMOUNT-1 trial enrolled participants with an average baseline BMI of 38 kg/m², demonstrating that tirzepatide achieved up to 22.5% body weight reduction over 72 weeks at the 15 mg maintenance dose.

However, BMI alone does not determine suitability under mounjaro eligible patients bmi uk criteria. Our prescribers assess waist circumference, existing weight management attempts including dietary modification and exercise programmes, and the presence of metabolic syndrome components. Patients must demonstrate commitment to lifestyle interventions alongside pharmacotherapy, as Mounjaro is licensed as an adjunct to reduced-calorie diet and increased physical activity, not as monotherapy [4].

Ethnic-Specific BMI Adjustments in UK Practice

NICE guidance recognises that mounjaro eligible patients bmi uk criteria should account for ethnic variation in metabolic risk. Adults from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds may qualify at lower BMI thresholds—typically 27.5 kg/m² instead of 30 kg/m², or 25 kg/m² with comorbidities instead of 27 kg/m²—due to higher proportional body fat and cardiometabolic risk at lower BMI values. Our clinical assessment incorporates these ethnicity-adjusted thresholds to ensure equitable access whilst maintaining prescribing safety.

Comorbidities That Modify Mounjaro Eligible Patients BMI UK Criteria

Weight-related comorbidities lower the BMI threshold in mounjaro eligible patients bmi uk criteria from 30 to 27 kg/m². Qualifying conditions include type 2 diabetes mellitus with inadequate glycaemic control, hypertension requiring pharmacological treatment, dyslipidaemia with elevated LDL cholesterol or triglycerides, obstructive sleep apnoea confirmed by sleep study, non-alcoholic fatty liver disease, polycystic ovary syndrome, or cardiovascular disease including previous myocardial infarction or stroke [5]. The presence of even one comorbidity alongside a BMI of 27 kg/m² makes patients potentially eligible, subject to prescriber assessment.

Type 2 diabetes represents the most common comorbidity in mounjaro eligible patients bmi uk criteria assessments. Tirzepatide functions as both a GIP and GLP-1 receptor agonist, delivering dual incretin action that improves glycaemic control whilst promoting weight loss. In the SURPASS-2 trial, participants achieved an average HbA1c reduction of 2.46% with the 15 mg dose, alongside 12.4 kg mean weight loss over 40 weeks [6]. Patients with type 2 diabetes and BMI 27-29.9 kg/m² may therefore derive dual metabolic benefits from Mounjaro treatment, available from £124.99 at Cured Pharmacy following clinical approval.

Treatment Active Ingredient BMI Requirement Starting Price
Mounjaro Tirzepatide BMI ≥30 or ≥27 with comorbidity From £145.00
Wegovy Injection Semaglutide BMI ≥30 or ≥27 with comorbidity From £89.00
Wegovy Oral Tablets Semaglutide BMI ≥30 or ≥27 with comorbidity From £83.00
Saxenda Liraglutide BMI ≥30 or ≥27 with comorbidity From £68.00
Mysimba Naltrexone/Bupropion BMI ≥30 or ≥27 with comorbidity From £125.95
Orlistat Orlistat BMI ≥30 or ≥28 with comorbidity From £32.00

Age and Medical History in Mounjaro Eligible Patients BMI UK Criteria

Mounjaro is licensed for adults aged 18 years and above, with no upper age limit specified in mounjaro eligible patients bmi uk criteria. However, elderly patients—particularly those over 75 years—require careful assessment due to increased risk of gastrointestinal adverse effects, potential for dehydration, and concurrent medication interactions. Our prescribers evaluate renal function, as tirzepatide does not require dose adjustment in mild to moderate renal impairment but is not recommended in severe impairment or end-stage renal disease.

Pregnancy and breastfeeding represent absolute contraindications in mounjaro eligible patients bmi uk criteria. Women of childbearing potential must use effective contraception during treatment and for at least two months after discontinuation, as animal studies suggest potential foetal harm [7]. Patients with a history of severe hypersensitivity reactions to tirzepatide or any excipient, or those with active gallbladder disease, may not meet eligibility standards. Every prescription requires completion of our online clinical assessment, reviewed by UK-registered prescribers before approval and dispensing.

Psychiatric History Considerations

Mental health conditions do not automatically exclude patients from mounjaro eligible patients bmi uk criteria, but require disclosure during assessment. GLP-1 receptor agonists have been associated with rare reports of suicidal ideation, necessitating careful evaluation in patients with depression, anxiety disorders, or previous suicide attempts. Our prescribers assess current psychiatric stability, ongoing treatment, and support systems before approving tirzepatide therapy. Patients must commit to monitoring mood changes and reporting any concerning symptoms during treatment.

Clinical Assessment Process for Mounjaro Eligible Patients BMI UK Criteria

Meeting mounjaro eligible patients bmi uk criteria begins with our three-minute online consultation, which collects medical history, current medications, allergies, and lifestyle factors. Patients self-report height and weight to calculate BMI, disclose any weight-related comorbidities, and answer questions about contraindications including thyroid history, pancreatitis, and pregnancy status. This information is reviewed by our UK-registered prescribers, who determine eligibility based on MHRA licensing standards and clinical safety protocols overseen by superintendent pharmacist Tarun Kumar (GPhC 2233073).

If mounjaro eligible patients bmi uk criteria are satisfied, the prescriber issues a private prescription and the medication is dispensed from our GPhC-registered pharmacy (9012511) with discreet next-day delivery. Patients receive the 2.5 mg starting dose for the first four weeks, with dose escalation to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and finally 15 mg maintenance dose at four-week intervals, as tolerated [8]. Ongoing monitoring includes weight tracking, side effect reporting, and clinical review at 12 weeks to assess treatment response. Patients who do not achieve at least 5% weight loss by 12 weeks may require treatment reassessment.

Accessing Mounjaro Under Eligible Patients BMI UK Criteria at Cured Pharmacy

Cured Pharmacy offers transparent access to Mounjaro for patients meeting mounjaro eligible patients bmi uk criteria, with pricing displayed upfront at £124.99 before consultation. New patients Save £20 off their first order using code Weightlossnew, reducing the initial cost to £124.99. Our lowest price guarantee ensures competitive UK pricing without compromising on clinical safety or genuine MHRA-licensed medication. Every pen is sourced directly from licensed UK wholesalers and dispensed in original manufacturer packaging with full patient information leaflets.

Understanding mounjaro eligible patients bmi uk criteria empowers patients to determine their likely eligibility before starting the assessment. If you have a BMI of 30 kg/m² or above, or 27 kg/m² with a weight-related health condition, and no contraindications, you may qualify for tirzepatide treatment. Our UK prescribers provide individualised clinical decisions based on your complete medical profile, ensuring safe and appropriate prescribing. Start your assessment today to access Mounjaro at the cheapest UK price, with discreet packaging and expert pharmaceutical support throughout your weight loss journey.

Why Choose Cured Pharmacy for Mounjaro Treatment

As a GPhC-registered online pharmacy, we combine clinical expertise with transparent pricing and genuine UK-licensed medicines. Our prescribers assess every patient against mounjaro eligible patients bmi uk criteria with the same rigour as face-to-face consultations, ensuring safe prescribing practices. Patients benefit from free clinical support, discreet delivery, and the assurance that every Mounjaro pen is authentic tirzepatide manufactured by Eli Lilly. With over 9,000 satisfied customers and superintendent pharmacist oversight, Cured Pharmacy delivers trusted weight loss treatment at competitive UK prices.

Scientific References

  1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Bunck, M. C. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 27 August 2026]
  2. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/ [accessed 27 August 2026]
  3. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE Clinical Guideline. [accessed 27 August 2026]
  4. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wadden, T. A. (2023). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 29(10), 2049-2057. [accessed 27 August 2026]
  5. Medicines and Healthcare products Regulatory Agency. (2023). Tirzepatide (Mounjaro) for weight management: regulatory approval and prescribing guidance. MHRA Public Assessment Report. [accessed 27 August 2026]
  6. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 27 August 2026]
  7. European Medicines Agency. (2023). Assessment report for Mounjaro: Procedure No. EMEA/H/C/005393/0000. EMA Committee for Medicinal Products for Human Use. [accessed 27 August 2026]
  8. Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., ... & SURPASS-3 Investigators. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 27 August 2026]
  9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 27 August 2026.
  10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 27 August 2026.
  11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 27 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

What BMI do I need to qualify under mounjaro eligible patients bmi uk criteria?
You need a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes or hypertension. Ethnicity-adjusted thresholds may apply for certain populations.
Do mounjaro eligible patients bmi uk criteria differ between NHS and private prescriptions?
MHRA licensing criteria remain the same, but NHS availability is currently limited. Private prescriptions through Cured Pharmacy follow identical clinical eligibility standards with transparent pricing from £124.99.
Can I access Mounjaro if my BMI is 29 kg/m² under mounjaro eligible patients bmi uk criteria?
Generally no, unless you meet ethnicity-adjusted thresholds or have exceptional clinical circumstances assessed by the prescriber. Standard mounjaro eligible patients bmi uk criteria require BMI ≥30 or ≥27 with comorbidity.
What comorbidities qualify under mounjaro eligible patients bmi uk criteria at BMI 27?
Type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, non-alcoholic fatty liver disease, or polycystic ovary syndrome are qualifying conditions.
How is BMI calculated for mounjaro eligible patients bmi uk criteria assessment?
BMI is calculated as weight in kilograms divided by height in metres squared. You provide height and weight during the online consultation, and our prescribers verify eligibility.
Are there age limits in mounjaro eligible patients bmi uk criteria?
Mounjaro is licensed for adults aged 18 and above with no upper age limit, though elderly patients require careful assessment for safety and tolerability.
Does pregnancy affect mounjaro eligible patients bmi uk criteria eligibility?
Yes, pregnancy and breastfeeding are absolute contraindications. Women of childbearing potential must use effective contraception during treatment and for two months after stopping.
How quickly can I start Mounjaro after meeting mounjaro eligible patients bmi uk criteria?
Once approved through our online assessment, Mounjaro is dispensed with next-day discreet delivery. New patients Save £20 using code Weightlossnew, reducing the price to £124.99.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Last reviewed: 27 August 2026

Last updated on 27 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 27 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (27 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.